A Mayo Clinic research team has found evidence suggesting that premenopausal women who are not at high risk of ovarian cancer should not have their ovaries removed for the purpose of cancer prevention. Premature removal of the ovaries can lead to a higher risk of anywhere from 8 to 18 chronic health conditions including coronary … Continued
(October 11, 2016) According to research published this month in the New England Journal of Medicine, the PARP inhibitor niraparib improves progression free survival in recurrent, platinum-sensitive women both with and without germline BRCA mutations. In a randomized, double-blind, phase III trial of over 550 women both with and without germline BRCA mutations, researchers found … Continued
Meet a Researcher: We had the chance to interview Hui Shen, PhD, a 2016 Liz Tilberis Early Career Award grantee to get to know her! Read our interview here. OCRFA: Tell us about yourself. Dr. Hui Shen: My name is Hui Shen. I am originally from China, and had lived in Hong Kong and Los … Continued
OCRFA and Dr. Elizabeth Swisher spoke about the exciting progress being made by the Stand Up to Cancer Ovarian Cancer Dream Team! The SU2C Ovarian Cancer Dream Team, funded by OCRFA and NOCC, got to work on year ago. Dr. Swisher, a gynecologic oncologist at the University of Washington and co-leader of the Dream Team, … Continued
(October 5, 2016) A new analysis published in the American Journal of Obstetrics and Gynecology determined the impact of gynecologic surgeon volumes on patient outcomes. Reviewing fourteen studies that involved over 700,000 women, the researchers found that low-volume surgeons (categorized as those performing the procedure approximately once a month or less) were found to have … Continued
(October 5, 2016) A team of researchers, including senior author and former OCRFA grantee Rugang Zhang, PhD, have been studying the relationship between PD-1 and PD-L1, a protein and an accompanying molecule, and t-cells, which are a body’s natural defense against tumor growth. PD-L1 can be found on both cancer cells and healthy cells but, … Continued
Research Advocate, Annie Ellis, recently attended the Biennial Ovarian Cancer Research Symposium presented by the Rivkin Center for Ovarian Cancer and the American Association for Cancer Research. Read her report, check out a poster on Beyond RECIST 1.1 and a poster on MAGENTA-Making Genetic Testing More Accessible.
On September 13th, Abcodia Incorporated, the makers of the ROCA Test, released this statement*, following the safety guidance put out by the FDA last week. ROCA Test sales are now suspended in the United States. *Note: The original publication of this article linked to an article that has since been archived. For more updated information, please visit … Continued
Meet Researcher Kris Wood, PhD! Q&A with Kris Wood, PhD Duke University 2015 Liz Tilberis Award OCRFA: Tell me about yourself. Kris Wood: I grew up in Georgetown, KY, a rural town in the central part of the state. My family lived in a house on my grandfather’s farm, which was a wonderful place to … Continued
(August 16, 2016) While primary cytoreductive surgery followed by chemotherapy is the standard of care for newly diagnosed women with advanced ovarian cancer, newly issued practice guidelines suggest that some patients may benefit more from first-line neoadjuvant chemotherapy (NACT) and followed by surgery. Last week, the Society for Gynecologic Oncology (SGO) and the American Society … Continued
(Aug 1. 2016) Results of a study reported last month in Cancer show that routine referral of women at high risk for ovarian cancer to genetic counseling promotes genetic testing and prophylactic surgery. Guidelines recommend genetic counseling and testing for women who have a pedigree suggestive of an inherited susceptibility for ovarian cancer (for example, … Continued
(July 28, 2016) A study published recently in JAMA Oncology showed that CA-125 tests and CT scans are routinely used in ovarian cancer surveillance testing, even though evidence has shown there is no clinical benefit to using these tests. There is no consensus on how to follow a patient in remission from ovarian cancer in … Continued
Get email updates about research news, action alerts, and ways to join the fight.
